Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 1—January 2007
Research

Model for Assessing Human Papillomavirus Vaccination Strategies

Elamin H. Elbasha*Comments to Author , Erik J. Dasbach*, and Ralph P. Insinga*
Author affiliations: *Merck Research Laboratories, North Wales, Pennsylvania, USA;

Main Article

Figure 5

A) Incidence of genital warts due to human papillomavirus (HPV) 6/11 infection among boys and men >12 years of age by strategy. B) Incidence of genital warts due to HPV 6/11 infection among girls and women >12 years, of age by strategy.

Figure 5. A) Incidence of genital warts due to human papillomavirus (HPV) 6/11 infection among boys and men >12 years of age by strategy. B) Incidence of genital warts due to HPV 6/11 infection among girls and women >12 years, of age by strategy.

Main Article

Page created: June 28, 2010
Page updated: June 28, 2010
Page reviewed: June 28, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external